Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Advances in regenerative medicine are rapidly transforming healthcare. A cornerstone of regenerative medicine is the introduction of cells that were grown or manipulated in vitro. Key questions that arise after these cells are re-introduced are: whether these cells are localized in the appropriate site; whether cells survive; and whether these cells migrate. These questions predominantly relate to the safety of the therapeutic approach (i.e. tumorigenesis), but certain aspects can also influence the efficacy of the therapeutic approach (e.g. site of injection). The European Medicines Agency has indicated that suitable methods for stem cell tracking should be applied where these methods are available. We here discuss the European regulatory framework, as well as the scientific evidence, that should be considered to facilitate the potential clinical implementation of magnetic resonance imaging contrast media to track implanted/injected cells in human studies.

Original publication

DOI

10.1002/cmmi.1547

Type

Journal article

Journal

Contrast Media Mol Imaging

Publication Date

11/2013

Volume

8

Pages

439 - 455

Keywords

Advanced Therapy Medicinal Products, Cell Therapy, Image Guidance, MRI, Regenerative Medicine, Theranostics, Therapeutic Monitoring, Tissue Engineering, cellular MRI, clinical translation, contrast agent, regulatory pathway, toxicity, Animals, Cell Movement, Cell Tracking, Humans, Magnetic Resonance Imaging, Regenerative Medicine, Stem Cells